Having trouble accessing articles? Reset your cache.

Cyclacel raises $15.2M ahead of AML Phase III

Cyclacel Pharmaceuticals Inc. (NASDAQ:CYCC) raised $15.2 million through the sale of 8.3 million

Read the full 130 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE